#1 Clinical Trials Search in Europe

Allogeneic Cd4+ And Cd8+ T Lymphocytes Ex Vivo Incubated With Synthetic Peptides Of The Viral Antigens Of Cytomegalovirus, Adenovirus And Epstein-Barr Virus

This article discusses a groundbreaking clinical trial investigating the use of allogeneic multi-virus specific T cells to treat chemotherapy-resistant viral infections in patients who have undergone stem cell transplantation. The therapy targets three common viruses: cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (AdV). This phase III study aims to evaluate the efficacy and safety of this innovative cellular therapy in improving outcomes for transplant patients struggling with persistent viral infections.

Table of Contents

What is Allogeneic Multivirus-Specific T Cell Therapy?

Allogeneic multivirus-specific T cell therapy is an innovative treatment designed to combat resistant viral infections in patients who have undergone stem cell transplantation. This therapy uses specially prepared T cells (a type of white blood cell) that have been trained to recognize and fight specific viruses[1].

The full name of this treatment is quite complex: “Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus.” Let’s break this down:

  • Allogeneic: This means the T cells come from a donor, not the patient themselves.
  • CD4+ and CD8+ T lymphocytes: These are two main types of T cells in our immune system.
  • Ex vivo incubated: The T cells are prepared outside the body in a laboratory.
  • Synthetic peptides of viral antigens: The T cells are exposed to artificial pieces of virus proteins to train them.
  • Cytomegalovirus (CMV), Adenovirus (AdV), and Epstein-Barr virus (EBV): These are the three viruses targeted by this therapy.

How Does It Work?

This therapy works by enhancing the patient’s immune system with specially prepared T cells. Here’s a simplified explanation of the process:

  1. T cells are collected from a donor (usually the same person who donated stem cells for the transplant).
  2. In the laboratory, these T cells are exposed to parts of CMV, AdV, and EBV viruses. This “trains” the T cells to recognize these specific viruses.
  3. The trained T cells are then given to the patient through an intravenous (IV) infusion.
  4. Once in the patient’s body, these T cells can recognize and attack the viruses, helping to clear the infection[1].

Who Can Benefit from This Treatment?

This therapy is specifically designed for patients who meet the following criteria:

  • Have undergone a hematopoietic stem cell transplantation (HSCT). This is a procedure often used to treat blood cancers, where a patient’s blood-forming stem cells are replaced with healthy ones.
  • Are suffering from a new or reactivated infection caused by CMV, EBV, or AdV.
  • The infection is resistant to standard antiviral treatments. This means that after two weeks of normal antiviral therapy, the amount of virus in their blood hasn’t decreased significantly[1].

Both adults and children (over 2 months old) may be eligible for this treatment.

The TRACE Clinical Trial

A large-scale clinical trial called TRACE (Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV) is currently underway to evaluate this therapy. This is a Phase III trial, which means it’s in the final stages of testing before potentially becoming widely available[1].

The main goal of the TRACE trial is to see how effective this T cell therapy is in treating resistant viral infections in stem cell transplant patients. Researchers will look at several factors, including:

  • How many patients clear the virus from their blood
  • How quickly the amount of virus in the blood decreases
  • Whether patients’ symptoms improve
  • How safe the treatment is
  • How it affects patients’ quality of life[1]

Potential Benefits

If successful, this therapy could offer several benefits:

  • Effective treatment for viral infections that don’t respond to standard medications
  • Potentially faster recovery from viral infections
  • Possible reduction in the need for long-term antiviral medications
  • Potential improvement in overall survival for stem cell transplant patients[1]

Safety Considerations

As with any new treatment, safety is a crucial concern. The TRACE trial is carefully monitoring for side effects, including:

  • Graft-versus-host disease (GvHD): A condition where donor cells attack the patient’s body. The trial excludes patients with severe GvHD.
  • Acute reactions: Such as chills, nausea, allergic reactions, or breathing problems during or shortly after the infusion.
  • Long-term effects: The trial will follow patients for several months to monitor for any delayed side effects[1].

Future Implications

If the TRACE trial shows positive results, this therapy could become a valuable tool in treating resistant viral infections in stem cell transplant patients. It might also pave the way for similar treatments targeting other viruses or conditions.

Moreover, this research contributes to our understanding of how to harness the immune system to fight diseases, potentially leading to advancements in other areas of medicine[1].

Aspect Details
Study Type Phase III clinical trial
Treatment Allogeneic multi-virus specific T cells targeting CMV, EBV, and AdV
Patient Population Adult and pediatric stem cell transplant recipients with chemotherapy-resistant viral infections
Primary Objectives Evaluate efficacy of T cell transfer in clearing viral infections and preventing disease progression
Secondary Objectives Assess GvHD incidence, toxicity, viral load changes, clinical response, overall survival, and quality of life
Administration Intravenous bolus injection or infusion
Follow-up Period 15 weeks post-treatment
Key Exclusion Criteria Acute GvHD > grade II, extensive chronic GvHD, high-dose steroid treatment, recent donor lymphocyte infusion

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the effectiveness of multi-specific T cell transfer in treating patients with chemotherapy-resistant viral infections after allogeneic stem cell transplantation. The study focuses on infections caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (AdV).
  • Who is eligible to participate in this trial? Eligible participants include adult and pediatric patients (over 2 months old) who have undergone stem cell transplantation and are suffering from new or reactivated CMV, EBV, or AdV infections that have not responded to standard antiviral treatment for two weeks. The original stem cell donor must be available and have an immune response to at least the virus causing the therapy-resistant infection.
  • How is the treatment administered? The treatment involves the infusion of allogeneic multi-virus specific T cells. These are T cells from the original stem cell donor that have been specially prepared to target the viruses causing the infection. The cells are administered intravenously as a bolus injection or infusion.
  • What are the main outcomes being measured in this study? The primary outcomes being measured are the percentage of patients achieving viral clearance (defined as two consecutive negative PCR tests) and the percentage of patients experiencing disease progression between Day 7 and Week 8 after the T cell transfer. Secondary outcomes include the incidence and severity of graft-versus-host disease (GvHD), changes in viral load, clinical symptom resolution, and overall survival.
  • Are there any potential risks or side effects associated with this treatment? While the study aims to assess the safety of the treatment, potential risks may include acute toxicity reactions on the day of T cell transfer, such as chills, nausea, vomiting, diarrhea, abdominal pain, allergic reactions, respiratory dysfunction, or headache. The study will also monitor for the development or worsening of graft-versus-host disease (GvHD) and any other adverse events throughout the trial period.

Ongoing Clinical Trials on Allogeneic Cd4+ And Cd8+ T Lymphocytes Ex Vivo Incubated With Synthetic Peptides Of The Viral Antigens Of Cytomegalovirus, Adenovirus And Epstein-Barr Virus

  • Study on Treating Resistant Viral Infections in Stem Cell Transplant Patients Using Allogeneic Multivirus-Specific T Cells

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands

Glossary

  • Allogeneic: Referring to cells or tissues that are taken from a different individual of the same species. In this context, it means the T cells come from the original stem cell donor, not the patient.
  • Stem Cell Transplantation: A procedure in which healthy blood-forming stem cells are used to replace damaged or diseased bone marrow. It's often used to treat certain cancers and blood disorders.
  • T Lymphocytes (T cells): A type of white blood cell that plays a central role in the immune response. In this therapy, these cells are specifically prepared to target certain viruses.
  • Cytomegalovirus (CMV): A common virus that can cause serious complications in people with weakened immune systems, such as transplant recipients.
  • Epstein-Barr Virus (EBV): A common herpes virus that can cause infectious mononucleosis and is associated with certain cancers, particularly in immunocompromised individuals.
  • Adenovirus (AdV): A group of viruses that can cause various illnesses, including respiratory infections, which can be severe in immunocompromised patients.
  • Graft-versus-Host Disease (GvHD): A potential complication of stem cell transplantation where the donor's immune cells attack the recipient's tissues.
  • PCR (Polymerase Chain Reaction): A laboratory technique used to detect and measure the presence of specific genetic material, such as viral DNA or RNA.
  • Viral Load: The amount of virus present in an infected person's blood or other bodily fluids.
  • Chemotherapy-refractory: Referring to an infection or condition that does not respond to standard treatment with chemotherapy or antiviral drugs.

References

  1. http://clinicaltrials.eu/trial/study-on-treating-resistant-viral-infections-in-stem-cell-transplant-patients-using-allogeneic-multivirus-specific-t-cells/